Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Two Strikes For Ketek: Cmtes. Want Bronchitis, Sinusitis Indications Rescinded

Executive Summary

FDA's Anti-Infective Drug and Drug Safety and Risk Management Advisory Committees are recommending stripping Sanofi-Aventis' Ketek of its bronchitis and sinusitis indications

You may also be interested in...



Antibiotics For ABS Should Have “Time To Symptom Relief” Trials, FDA Says

During clinical trials of antibiotics for treating acute bacterial sinusitis, "time to clinical success" is the recommended primary efficacy endpoint, FDA says in new draft guidance on developing ABS drugs

Antibiotics For ABS Should Have “Time To Symptom Relief” Trials, FDA Says

During clinical trials of antibiotics for treating acute bacterial sinusitis, "time to clinical success" is the recommended primary efficacy endpoint, FDA says in new draft guidance on developing ABS drugs

Antibiotic Efficacy Rereview Would Be Triggered Only By Safety Issues – FDA

Absent safety concerns, FDA is not planning to seek superiority trials for currently-marketed antibiotics, despite advisory committee concerns about the approval standards used for Sanofi-Aventis' Ketek (telithromycin)

Related Content

UsernamePublicRestriction

Register

PS047858

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel